• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

For many suffering from depression, traditional therapies and medications are not effective. Personalized treatment may be the answer.

Cue is a digital intervention platform that translates passively acquired normal smartphone sensor data into personalized micro-interventions designed to improve mental health. We analyzed the most effective-fit personal ML models for each subject using Shapley values to discover their predictors of feature and reveal distinct characteristics that can be used to predict changes in mood as time passes.

Predictors of Mood

Depression is the leading cause of mental illness in the world.1 Yet only half of those with the condition receive treatment. In order to improve outcomes, clinicians need to be able to identify and treat patients who have the highest probability of responding to certain treatments.

Personalized depression treatment resistant depression treatment is one method of doing this. Using mobile phone sensors and an artificial intelligence voice assistant, and other digital tools, researchers at the University of Illinois Chicago (UIC) are developing new methods to determine which patients will benefit from the treatments they receive. Two grants worth more than $10 million will be used to discover biological and behavioral indicators of response.

To date, the majority of research on factors that predict depression treatment effectiveness has been focused on the sociodemographic and clinical aspects. These include demographics like gender, age, and education, as well as clinical aspects like severity of symptom, comorbidities and biological markers.

Few studies have used longitudinal data in order to predict mood of individuals. They have not taken into account the fact that mood can vary significantly between individuals. Therefore, it is important to develop methods which permit the determination and quantification of the individual differences in mood predictors, treatment effects, etc.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This allows the team to develop algorithms that can systematically identify various patterns of behavior and emotions that are different between people.

In addition to these methods, the team developed a machine-learning algorithm that models the dynamic predictors of each person's depressed mood. The algorithm combines these individual characteristics into a distinctive "digital phenotype" for each participant.

This digital phenotype was found to be associated with CAT DI scores, a psychometrically validated severity scale for symptom severity. However the correlation was tinny (Pearson's r = 0.08, the BH-adjusted p-value was 3.55 1003) and varied widely among individuals.

Predictors of symptoms

Depression is one of the most prevalent causes of disability1, but it is often underdiagnosed and undertreated2. In addition, a lack of effective treatments and stigmatization associated with depression disorders hinder many people from seeking help.

To assist in individualized treatment, it is important to identify the factors that predict symptoms. The current methods for predicting symptoms rely heavily on clinical interviews, which aren't reliable and only identify a handful of features associated with depression.

Machine learning can be used to integrate continuous digital behavioral phenotypes of a person captured by smartphone sensors and a validated online tracker of mental health (the Computerized Adaptive Testing Depression Inventory, the CAT-DI) together with other predictors of symptom severity could increase the accuracy of diagnostics and the effectiveness of treatment for depression. Digital phenotypes are able to provide a wide range of unique actions and behaviors that are difficult to capture through interviews, and allow for continuous, high-resolution measurements.

The study involved University of California Los Angeles students with mild to severe depression symptoms who were taking part in the Screening and Treatment for Anxiety and Depression program29 developed as part of the UCLA Depression Grand Challenge. Participants were referred to online support or to clinical treatment depending on the severity of their depression. Patients who scored high on the CAT-DI scale of 35 or 65 were given online support by a coach and those with scores of 75 patients were referred to clinics in-person for psychotherapy.

Participants were asked a series of questions at the beginning of the study regarding their demographics and psychosocial traits. These included age, sex, education, work, and financial status; whether they were divorced, partnered or single; their current suicidal ideation, intent or attempts; and the frequency at the frequency they consumed alcohol. The CAT-DI was used to assess the severity of depression-related symptoms on a scale ranging from 100 to. The CAT-DI assessment was conducted every two weeks for participants who received online support, and weekly for those who received in-person assistance.

Predictors of the Reaction to Treatment

A customized treatment for depression is currently a top research topic, and many studies aim at identifying predictors that allow clinicians to identify the most effective drugs for each patient. Particularly, pharmacogenetics is able to identify genetic variants that influence how the body metabolizes antidepressants. This allows doctors to select drugs that are likely to be most effective for each patient, reducing the time and effort in trial-and-error procedures and avoid any adverse effects that could otherwise hinder the progress of the patient.

Another promising method is to construct prediction models using multiple data sources, combining data from clinical studies and neural imaging data. These models can then be used to determine the most effective combination of variables that are predictive of a particular outcome, like whether or not a non drug treatment for anxiety and depression is likely to improve mood and symptoms. These models can also be used to predict the patient's response to a treatment they are currently receiving and help doctors maximize the effectiveness of the treatment currently being administered.

A new era of research uses machine learning methods such as supervised learning and classification algorithms (like regularized logistic regression or tree-based methods) to combine the effects of many variables and improve the accuracy of predictive. These models have been proven to be useful in predicting treatment outcomes such as the response to antidepressants. These models are getting more popular in psychiatry and it is likely that they will become the standard for future clinical practice.

Research into depression's underlying mechanisms continues, in addition to predictive models based on ML. Recent research suggests that depression is related to the dysfunctions of specific neural networks. This theory suggests that individual depression treatment will be built around targeted treatments that target these circuits in order to restore normal function.

Internet-based-based therapies can be an option to accomplish this. They can provide more customized and personalized experience for patients. A study showed that an internet-based program improved symptoms and led to a better quality of life for MDD patients. In addition, a controlled randomized trial of a personalized approach to depression treatment showed an improvement in symptoms and fewer side effects in a significant proportion of participants.

Predictors of Side Effects

A major issue in personalizing depression treatment involves identifying and predicting which antidepressant medications will cause very little or no side effects. Many patients are prescribed various medications before finding a medication that is effective and tolerated. Pharmacogenetics offers a fascinating new avenue for a more efficient and specific approach to choosing antidepressant medications.

Many predictors can be used to determine which antidepressant to prescribe, 1borsa.com including genetic variants, phenotypes of patients (e.g. sexual orientation, gender or ethnicity) and comorbidities. However it is difficult to determine the most reliable and valid predictors for a particular treatment is likely to require randomized controlled trials of significantly larger numbers of participants than those that are typically part of clinical trials. This is because the detection of moderators or interaction effects may be much more difficult in trials that only focus on a single instance of treatment per patient, rather than multiple episodes of treatment over time.

Furthermore, the prediction of a patient's response to a specific best medication to treat anxiety and depression; check out this site, is likely to require information about comorbidities and symptom profiles, in addition to the patient's personal experiences with the effectiveness and tolerability of the medication. At present, only a handful of easily measurable sociodemographic variables as well as clinical variables appear to be reliable in predicting the response to MDD. These include gender, age, race/ethnicity, BMI, SES and the presence of alexithymia.

The application of pharmacogenetics to treatment for depression is in its beginning stages, and many challenges remain. First it is necessary to have a clear understanding of the genetic mechanisms is essential, as is a clear definition of what is a reliable predictor of treatment response. In addition, ethical concerns such as privacy and the appropriate use of personal genetic information must be considered carefully. Pharmacogenetics can, in the long run reduce stigma associated with mental health treatment and improve the quality of treatment. But, like any other psychiatric treatment, careful consideration epilepsy and depression treatment application is required. At present, the most effective method is to offer patients various effective depression medication options and encourage them to speak openly with their doctors about their experiences and concerns.